Menu Search
Equities

Nova Eye Medical Ltd

ELXMF:PKC

Nova Eye Medical Ltd

Actions
  • Price (USD)0.10
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Apr 25 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Nova Eye Medical Ltd grew revenues 36.90% from 17.13m to 23.45m while net income improved from a loss of 15.29m to a smaller loss of 8.79m.
Gross margin86.64%
Net profit margin-37.49%
Operating margin-37.72%
Return on assets-29.18%
Return on equity-39.49%
Return on investment-36.41%
More ▼

Cash flow in AUDView more

In 2024, cash reserves at Nova Eye Medical Ltd fell by 1.27m. Cash Flow from Financing totalled 6.91m or 29.48% of revenues. In addition the company used 7.86m for operations while cash used for investing totalled 325.00k.
Cash flow per share-0.0284
Price/Cash flow per share--
Book value per share0.0932
Tangible book value per share0.0444
More ▼

Balance sheet in AUDView more

Nova Eye Medical Ltd has a Debt to Total Capital ratio of 13.57%, a higher figure than the previous year's 3.85%.
Current ratio2.60
Quick ratio1.84
Total debt/total equity0.157
Total debt/total capital0.1357
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.